Richard J D Hatley
Overview
Explore the profile of Richard J D Hatley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hryczanek H, Barrett J, Barrett T, Burley G, Cookson R, Hatley R, et al.
J Med Chem
. 2024 Oct;
67(21):19689-19715.
PMID: 39417301
The αβ integrin has been identified as a target for the treatment of fibrotic diseases, based on the role it has in activating TGF-β, a protein implicated in the pathogenesis...
2.
Procopiou P, Barrett J, Crawford M, Hatley R, Hancock A, Pritchard J, et al.
J Med Chem
. 2024 Sep;
67(19):17497-17519.
PMID: 39269712
A series of 3-aryl(()-3-fluoropyrrolidin-1-yl)butanoic acids were developed as potent orally bioavailable αβ integrin inhibitors. Starting from a zwitterionic peptidomimetic series optimized for inhaled administration, the balancing of potency and passive...
3.
Hatley R, McLachlan S, Baster K, Gelder L, Macdonald S
J Med Chem
. 2021 Dec;
65(1):37-57.
PMID: 34931848
A bibliometric study of authors across medicinal chemistry journals over 20 years reveals important trends. Most United States (US) based authors are assigned as racially/ethnically Asian or White; few are...
4.
Wilkinson A, John A, Barrett J, Gower E, Morrison V, Man Y, et al.
Eur J Pharmacol
. 2021 Nov;
913:174618.
PMID: 34762934
Fibrosis is the formation of scar tissue due to injury or long-term inflammation and is a leading cause of morbidity and mortality. Activation of the pro-fibrotic cytokine transforming growth factor-β...
5.
Hatley R, Procopiou P, McLachlan S, Westendorf L, Meanwell N, Ewing W, et al.
J Med Chem
. 2020 Oct;
63(23):14336-14356.
PMID: 33103431
Writing scientific articles is immensely rewarding but challenging. This Perspective provides the medicinal chemist with background and advice on the art and process of writing manuscripts and complements the instructions...
6.
Macdonald S, Hatley R
Drug Discov Today
. 2020 Jan;
25(3):599-609.
PMID: 31981481
Pharmaceutical innovation is in short supply. Many diagnoses have been made and remedies prescribed by those in the industry and those that comment on it. There is much less practical...
7.
Hatley R, Barrett T, Slack R, Watson M, Baillache D, Gruszka A, et al.
ChemMedChem
. 2019 Jun;
14(14):1315-1320.
PMID: 31207080
Up to 45 % of deaths in developed nations can be attributed to chronic fibroproliferative diseases, highlighting the need for effective therapies. The RGD (Arg-Gly-Asp) integrin αvβ1 was recently investigated...
8.
Hatley R, Macdonald S, Slack R, Le J, Ludbrook S, Lukey P
Angew Chem Int Ed Engl
. 2017 Sep;
57(13):3298-3321.
PMID: 28944552
There is a requirement for efficacious and safe medicines to treat diseases with high unmet need. The resurgence in αv-RGD integrin inhibitor drug discovery is poised to contribute to this...
9.
Nanthakumar C, Hatley R, Lemma S, Gauldie J, Marshall R, Macdonald S
Nat Rev Drug Discov
. 2015 Sep;
14(10):693-720.
PMID: 26338155
Fibrosis, which leads to progressive loss of tissue function and eventual organ failure, has been estimated to contribute to ~45% of deaths in the developed world, and so new therapeutics...
10.
Borthwick A, Davies D, Exall A, Hatley R, Hughes J, Irving W, et al.
J Med Chem
. 2006 Jul;
49(14):4159-70.
PMID: 16821776
A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption...